Trial Profile

Expanded Access Use of Derazantinib for Patients With Locally Advanced, Inoperable or Metastatic iCCA Harbouring FGFR Genomic Alterations

Status: Completed

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 10 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Derazantinib (Primary)
Indications Cholangiocarcinoma
Focus Expanded access; Therapeutic Use

Most Recent Events

06 Apr 2025 Status changed from recruiting to completed.
12 Oct 2020 Results of pooled analysis from two clinical studies and an expanded access program (n=23), presented in a Basilea Pharmaceutica Ltd media release.
12 Oct 2020 According to a Basilea Pharmaceutica Ltd media release, results of pooled analysis from two clinical studies and an expanded access program was presented at the Molecular Analysis for Precision Oncology (MAP) Virtual Congress 2020 organized by the European Society for Medical Oncology (ESMO).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com